Suven Life Sciences has secured two product patent from Canada and USA corresponding to the New Chemical Entities for the treatment
of disorders associated with Neurodegenerative diseases and patents are valid through 2034.
The granted claims of the patents include the class of selective 5-HT6 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia and sleep disorders like Narcolepsy etc.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
